Citations

Mayo Clinic

Clear

88156 citation(s) found for "NA".

Automated Detection of Motor Speech Disorders and Subtype Classification
Wang, Fenqi , Utianski, Rene L. , Barnard, Leland R , Stricker, John L. , Meade, Gabriela , Jones, David T. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R. , Meade, Gabriela , Jones, David T , Whitwell, Jennifer , Josephs, Keith A , Duffy, Joseph R , Botha, Hugo , Utianski, Rene L , Barnard, Leland , Clark, Heather M. , Botha, Hugo , Wang, Fenqi

No container title available | July 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.16.26358268 | PMID 42528514 Get It

Abstract Motor speech disorders (MSDs) are early markers of neurological disease, but expert perceptual analysis is rarely available outside specialized centers. Automated speech analysis offers a scalable alternative, yet prior studies have not systematically compared modeling approaches or assessed clinically relevant metrics in independent datasets. This study compared static acoustic features, articulatory informed Phonet features, and self-supervised pretrained models for binary and multi label MSD classification. We trained and evaluated models on 583 speech samples using speaker level splits. Baseline models included logistic regression and Gated Recurrent Units (GRUs) trained on eGeMAPS and MFCCs. We extracted three types of Phonet derived features and evaluated pretrained HuBERT and SSAST models in frozen, partially fine-tuned, and fully fine-tuned configurations. Binary classification distinguished MSDs from controls, while multi label classification identified six MSD subtypes. Models were assessed using validation AUC, and cut points were tested on two independent datasets. Pretrained and Phonet based models substantially outperformed static acoustic features. In binary classification, HuBERT achieved the highest AUC (0.95), while compact Phonet derived GRUs achieved comparable performance (up to 0.94). These models generalized well to independent datasets, maintaining high sensitivity (0.94) and specificity (0.97). In multi label classification, Phonet models achieved the highest macro average AUC (0.86), but threshold-based subtype performance declined on unseen data. Automated MSD detection is feasible and clinically promising. Binary classification generalized well, whereas multi label classification showed limited threshold stability across datasets.
Advances in the management of Hepatorenal syndrome
Jothimani, Dinesh, Khan, Sarah, Devireddy, Sravanthi, Rela, Mohamed, Kamath, Patrick, Jothimani, Dinesh , Rela, Mohamed

Current Opinion in Nephrology & Hypertension | July 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mnh.0000000000001212 | PMID 42471785 Get It

Purpose of review Hepatorenal syndrome (HRS) is the extreme manifestation of acute renal dysfunction in patients with cirrhosis, resulting from systemic vasodilation and renal vasoconstriction, leading to a reduction in the glomerular filtration rate. Recent findings The diagnostic criteria redefined diagnostic criteria for HRS-AKI (Hepatorenal syndrome -Acute kidney injury) as our understanding of disease progression has improved. This understanding of the HRS disease process guides current management, with the combination of intravascular volume expansion and vasoconstrictor therapy being the cornerstone of treatment. In addition to treatment selection, timing of treatment initiation, duration, dosage, and monitoring during treatment are decisive factors in HRS outcomes. Pathogenesis of HRS-AKI may be different in patients with acute-on-chronic liver failure (ACLF) in comparison to decompensated cirrhosis. Unfortunately, outcomes remain poor with medical therapies alone and a high risk of disease recurrence exists for HRS-AKI with persistence of the cirrhotic milieu. Liver transplantation remains the only definitive treatment of HRS-AKI. Given the critical nature of HRS-AKI, a multidisciplinary approach involving hepatologists, nephrologists, and intensive care physicians is essential for optimal clinical management. Summary Patients with HRS-AKI should be managed ideally in tertiary care centers and referred for liver transplantation promptly when eligible.
Abstract A046: Pre-diagnostic clinical-trajectory signatures of early-onset pancreatic cancer
Li, Jianfu Li, Yang, Yi , MIchael, Wallace, Bi, Yan, Yang, Yingyun

Cancer Research | July 18, 2026 | Volume: 86 | Issue: 14_Supplement | Pages: A046-A046

10.1158/1538-7445.rareca26-a046 Get It

Abstract Background: Early-onset pancreatic cancer (EOPC; age <50 y at diagnosis) is rare (≈1.3/100,000), biologically distinct, and germline-enriched (BRCA1/2, PALB2, ATM, CDKN2A, Lynch). Despite NCCN and CAPS Consortium recognition, its pre-diagnostic electronic health record (EHR) trajectory is uncharacterized. We sought reproducible signatures to guide subtype-aware surveillance for this under-screened young-adult population, where conventional guidelines do not apply. Methods: We assembled an EOPC cohort from Mayo Clinic (3 sites, 2001–2023; n=169 EOPC, n=3,162 older-onset PDAC), identified by ICD-10 C25.0–C25.3, C25.7, C25.9 or ICD-9 157.x with age <50 at first diagnosis. For each patient, 3-year pre-diagnostic trajectories of 10 routine laboratory analytes (bilirubin, CA 19-9, CEA, lipase, amylase, glucose, HbA1c, ALT, AST, alkaline phosphatase) were summarized over 30/90/180/365-day windows (mean, slope, delta; 1,706 features total; 131 retained at ≥10% non-zero). Features were winsorized (1–99 pct), standardized, and projected onto 15 PCA components capturing 81.7% variance. K-means clustering (k=2–6, min cluster fraction ≥10%) was assessed by silhouette and 100-resample bootstrap Adjusted Rand Index (ARI). Cluster signatures were compared against the older-onset PDAC cohort projected into the same component space. Results: Two reproducible pre-diagnostic clusters emerged (k=2; silhouette 0.469; bootstrap ARI 0.440). Cluster A: "occult prodrome" (87.0%; n=147; mean age 44.9 y) showed no clear signal across the 10 monitored analytes, with all analyte z-scores near zero through the 3-year window. Cluster B: "metabolic-biliary active" (13.0%; n=22; mean age 44.4 y) was characterized by elevated mean HbA1c (z=+1.08), rising bilirubin slope (z=+0.54), and rising ALT/alkaline phosphatase slopes (z=+0.51 each), consistent with combined diabetic-onset and biliary-obstructive prodrome. The two-cluster structure reproduced in older-onset Mayo PDAC at 87.3% / 12.7%, nearly identical to the EOPC distribution, indicating a fundamental pre-diagnostic dichotomy of pancreatic cancer rather than an age-specific phenomenon. The dominant occult phenotype across age strata indicates that lab-trajectory–anchored surveillance can only address the active minority and motivates complementary genetic-, demographic-, or imaging-anchored pathways for the occult majority. Conclusions: EOPC pre-diagnostic trajectories partition into a dominant occult prodrome (∼87%) without detectable signal in the 10 routine labs evaluated and a minority metabolic-biliary active prodrome (∼13%) with combined diabetic and obstructive features. The high occult prevalence motivates germline-guided active surveillance for genetically at-risk young adults rather than symptom-driven workup, anchoring next-generation surveillance trial designs in rare and hereditary pancreatic malignancies. External validation in independent institutional cohorts (Mayo Clinic Platform / MERCI, or comparable EHR networks) is the planned next step. Citation Format: Jianfu Li Li, Yingyun Yang, Wallace MIchael, Yan Bi. Pre-diagnostic clinical-trajectory signatures of early-onset pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr A046.
Abstract A018: Identifying potential cell-surface targets for therapeutic treatment of DICER1 -related cancers
McNally, Brenya, Mallinger, Paige, Huntsman, David, FCCMG, Zhang, Joyce , Fraire, Claudette R. , Schoettler, Peter J., Schultz, Kris Ann P. , Chen, Kenneth S., Wang, Yemin , Schoettler, P.J.

Cancer Research | July 18, 2026 | Volume: 86 | Issue: 14_Supplement | Pages: A018-A018

10.1158/1538-7445.rareca26-a018 Get It

Abstract INTRODUCTION: Pleuropulmonary blastoma (PPB) and Sertoli-Leydig cell tumor (SLCT) are DICER1-related tumors for which novel therapies are urgently needed. A subset of Wilms tumors are also associated with germline or somatic variants in DICER1. Current therapies include cytotoxic chemotherapy, radiation, and surgery, but there are limited options for patients with recurrent disease. Antibody-Drug Conjugates (ADC) have emerged as promising therapies for several solid tumors. Aberrantly expressed cell surface proteins, including Preferentially Expressed Antigen in Melanoma (PRAME), represent potential targets for immunotherapeutic treatments like CAR-T cell and antibody-based therapies in malignant cancers, including DICER1-associated tumors. METHODS: Individuals diagnosed with PPB, SLCT, and Wilms tumor who enrolled in the International PPB/DICER1 Registry, International OTST Registry, and/or UT Southwestern Pediatric Hematology-Oncology Biorepository were selected for analysis. We analyzed ten PPB samples (four PDX, six primary tumor), four SLCT samples (all primary tumor), and 54 Wilms tumor samples (4 PDX, 50 primary tumor). DICER1 hotspot variants were verified in all 14 PPB and SLCT samples, while none of the Wilms tumor samples we analyzed exhibited DICER1 hotspot variants. Mapped and normalized whole-transcriptome sequencing reads were used to examine expression of 73 targets of antibody- or cell-based therapies that are clinically approved or under clinical investigation on clinicaltrials.gov. Genes with a median expression exceeding 2.5 transcripts per million (TPM) were considered expressed in a given tumor type; this threshold was selected to be permissive in identifying potential targets for further evaluation. RESULTS: Of the 73 genes of interest, 21 targetable cell-surface genes met a median expression threshold of 2.5 TPM in at least one tumor type: 11 genes in PPB, 16 in SLCT, and 14 in Wilms. Seven genes (FN1, PRAME, MCAM, CD248, IL11RA, CD276 (B7-H3), and MRC2) were expressed at this level in all three tumor types. Additional genes were expressed above this level in only two of the tumor types; PDGFRA in PPB and SLCT; GPC2 and TYRO3 in SLCT and Wilms tumor; and CSPG4, ERBB2, FZD10 in PPB and Wilms tumor. Six genes were exclusively expressed in SLCT (AXL, GPNMB, PROM1, KDR, ITGA6, FGFR4), and two were unique to Wilms tumor (GPC1, ULBP3). Of these, PRAME was previously reported as frequently expressed in DICER1-associated tumors; little has been reported about the remaining potential targets. CONCLUSION: PPB, SLCT, and Wilms tumor express several potential immunotherapy targets by RNA-seq. Expression of these potential targets should be investigated by immunostaining in a wider panel of tumors. Further study on the potential for ADCs or CAR-T cell therapies to treat DICER1-related conditions is needed. Citation Format: Brenya McNally, BS, Paige H.R. Mallinger, MS, David Huntsman, MD, FRCPC, FCCMG, Yemin Wang, PhD, Joyce Zhang, PhD, Claudette R. Fraire, PhD, Peter J. Schoettler, MD, Kris Ann P. Schultz, MD, Kenneth S. Chen, MD. Identifying potential cell-surface targets for therapeutic treatment of DICER1-related cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr A018.
Unintentional Weight Loss Does Not Predict Poor Outcomes in Zenker Diverticulum
Allen, Jacqueline , Belafsky, Peter C., deSilva, Brad W. , Dhar, Shumon I. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Gardner, Glendon M., Johnson, Christopher, Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L., Matrka, Laura , Piraka, Cyrus, Ramaswamy, Apoorva, Rosen, Clark A. , Sibley, Haley , Wright, Carter, Yang, Z. Mike, Young, VyVy N. , Postma, Gregory, Howell, Rebecca J. , Allen, Jacqui , Amin, Milan R , Bayan, Semirra L. , deSilva, Brad , Dhar, Shumon I , Ekbom, Dale , Fritz, Mark , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Sibley, Haley C , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Schuman, Ari D. , Altaye, Mekibib , Belafsky, Peter C. , Gardner, Glendon M., Guardiani, Elizabeth , Madden, Lyndsay L. , Mayerhoff, Ross , Piraka, Cyrus , Ramaswamy, Apoorva Tewari , Tabangin, Meredith E. , Postma, Gregory

The Laryngoscope | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70734 | PMID 42470432 Get It

ABSTRACT Objective Weight loss is frequently considered a cardinal presenting symptom for patients with Zenker diverticulum (ZD). We hypothesized that weight loss in patients with cricopharyngeal muscle dysfunction (CPMD), with or without diverticula, was associated with the length of symptoms and size of diverticulum. Methods Prospective, multicenter observational study of CPMD patients with and without diverticula reporting unintentional weight loss (+WL) or no weight loss (−WL) prior to enrollment in the Prospective Outcomes of Cricopharyngeal Hypertonicity (POuCH) database. Complications and symptom response using a patient reported outcome measure, the Eating Assessment Tool (EAT‐10), were compared. Results Of 427 patients, 101 (23.6%) were +WL. Median weight loss was 14 pounds (interquartile range [IQR] 10–25). +WL cohort had a mean age of 71.5 (standard deviation [SD] 11.5) vs. 67.9 in −WL (SD 11.6, p = 0.007). Mean preoperative EAT‐10 score was 24.7 in +WL (SD 9.7) and 14.8 in −WL (SD 8.8, p < 0.0001). Higher preoperative weight loss was associated with higher preoperative EAT‐10 ( p < 0.0001, Spearman's ρ = 0.43). Size of diverticulum was associated with WL ( p = 0.003), but weight loss was highest in both large diverticula and CP bars. Duration of symptoms was not associated with weight loss ( p = 0.30). Postoperative complications in +WL and −WL patients were similar ( p = 0.78). Conclusion Unintentional weight loss is common with ZD. Patients with worse dysphagia are more likely to have more weight loss. Weight loss does not increase with the size of the diverticulum or length of symptoms. Surgery has a similar safety profile with greater improvement in dysphagia in patients reporting weight loss. Level of Evidence 3.
Nutritional interventions in cardiac rehabilitation: current evidence, evidence gaps, and future directions—a scoping review
Elalfy, Aya, Abdelnabi, Mahmoud , Mohamed, Ahmed Elmorsy, VanDolah, Hunter , Sayed, Rana S., Kholeif, Zeyad, Rashwan, Rana , Ibrahim, Ramzi , Perone, Francesco , Arsanjani, R A, S Sayed, Rana , J Thomas, Randal, Ayoub, Chadi , VanDolah, Hunter , Perone, Francesco , Kholeif, Zeyad , Rashwan, Rana , Ibrahim, Ramzi , Thomas, Randal J. , Arsanjani, Reza

European Journal of Preventive Cardiology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag375 | PMID 42480502 Get It

Abstract Aims Nutritional counselling is a core component of cardiac rehabilitation (CR), yet the evidence base for specific dietary interventions within CR remains fragmented. This scoping review aimed to map the range of nutritional interventions evaluated in adult CR programmes, characterize their reported outcomes, and identify key gaps in current evidence and practice. Methods and results Following the Arksey and O’Malley framework and reporting according to PRISMA-ScR, a systematic search of PubMed, Embase, Web of Science, and Cochrane Library was conducted from inception to June 2026. Eligible studies included randomized controlled trials, non-randomized trials, and observational studies evaluating an explicitly described nutritional intervention within a structured CR programme in adults with established cardiovascular disease. Of 2765 identified records, 35 studies met eligibility criteria. Interventions spanned Mediterranean and heart-healthy dietary patterns, calorie-restriction and weight-loss programmes, comprehensive lifestyle interventions, structured nutrition education and counselling, supplementation, functional foods, and individualized diet prescriptions. Across categories, improvements in body weight, central adiposity, and adherence to cardioprotective dietary recommendations were commonly reported, particularly when nutrition was delivered with repeated contact and individualized support. Effects on lipid profiles, inflammatory markers, blood pressure, functional capacity, and clinical outcomes were more variable. Conclusion Nutritional interventions within CR were most consistently associated with improvements in intermediate behavioural, anthropometric, and cardiometabolic outcomes, particularly when structured and reinforced over time. However, heterogeneity in study design, intervention delivery, comparator groups, outcome reporting, and follow-up duration precludes definitive conclusions about comparative efficacy, optimal intervention format, or the magnitude of benefit. Greater standardization, longer follow-up, and further evaluation of personalized nutritional strategies are needed to strengthen the nutritional component of CR.
Clarifying risk-factor associations with quantitative breast tumor features: a pooled analysis of 24 studies
Adams, Daniel , Hurson, Amber N. , Ahearn, Thomas U, Andrulis, Irene L, Antoniou, Antonis C, Auvinen, Päivi, Bane, Anita, González, Amy Berrington de , Bodelon, Clara, Bolla, Manjeet K. , Borrero, Maria , Brenner, Hermann, Brock, Ian W., Camp, Nicola J. , Cessna, Melissa H., Chanock, Stephen J, Chenevix-Trench, G, Copson, ER, Fh, Couch, Devilee, P, Easton, Douglas F, Eccles, Diana, Figueroa, Jonine D, Glendon, Gord, Hamann, U, Hartman, Mikael, Heemskerk-Gerritsen, Bernadette A M, Hodge, James M, Holleczek, Bernd, Hollestelle, A M, Mj, Hooning, Investigators, kConFab, Amor, David, Andrews, Lesley , Antill, Y , Rl, Balleine, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Bodek, Simon, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Caldon, Liz, Campbell, Ian, Chakrabarti, Anannya , Chauhan, Deepa, Chauhan, Manisha, Christian, Alice, Cohen, Paul, Colley, Alison, Cui, James, Courtney, Eliza, Cummings, Margaret, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Duijf, Pascal, Edwards, Stacey, Farshid, Gelareh , Fellows, AM, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet , Friedlander, Michael, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Harraka, Philip, Hayward, Nick, Hoskins, Cass , Hunt, Clare, James, Paul, Jenkins, Mark, Kidd, Alexa, Koehler, Jessica, Kollias, J, Lakhani, Sunil, Lawrence, Mitchell, Lee, Jason , Li, Shuai, Lindeman, Geoff, Lippey, Jocelyn, Lipton, Lara, Loi, Sherene, Mann, Graham, Marsh, Deborah, McLachlan, Sue Anne, Reed, Amy McCart, Milne, Roger, Nightingale, Sophie , O’Connell, Shona, O’Sullivan, Sarah, Reilly, Robert O', Ortega, David Gallego, Pachter, Nick, Pang, Jia-Min, Pathak, Gargi, Patterson, Briony, Phillips, Kelly, Pieper, Ellen, Ramus, Susan, Rickard, Edwina, Ragunathan, Abi, Robinson, Bridget, Skandarajah, Anita, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Scott, Rodney, Scott, Clare, Sexton, Adrienne, Shaw, Joanne, Shelling, Andrew, Srinivasa, Shweta , Simpson, Peter, Mc, Southey, Spurdle, Amanda, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, A H, Tucker, Kathy , Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, I, Young, Mary Ann, Zaheed, Milita , Investigators, S On Behalf Of The Chlovis Study, Tan, Veronique Kiak Mien , Lim, Geok Hoon, Tan, Ern Yu , Tan, Su-Ming, Iau, Philip Tsau Choong , Jakubowska, A, Jones, Michael E. , Jones, Louise , Jones, Brandt, Jung, Audrey, Kaaks, Rudolf, Keeman, Renske , Lawrence, Scott, Li, J M, Lubiński, J, Mannermaa, Arto, Manoochehri, Mehdi, Martens, John W M, Mesker, Wilma E, Muhammad, Noor , Obi, Nadia, Olson, Janet E, Patel, Alpa V, Prajzendanc, Karolina , Ruddy, Kathryn J, Safizadeh, Fatemeh , Schöttker, Ben, Tengström, Maria , Le, Teras, Timmermans, M, Tollenaar, RA, Vachon, Celine M, Wang, Q, Yang, Xiaohong R, Zamora, M Pilar, Chang-Claude, Jenny, Schmidt, M K, Pharoah, Paul D P, Abubakar, Mustapha, Eccles, Diana , Ahearn, Thomas U. , Eccles, Diana , Jones, Michael E , Jones, J. Louise , Berrington de Gonzalez, Amy , Antoniou, Antonis C. , Bane, Anita, Behrens, Sabine , Białkowska, Katarzyna , Bodelón, Clara , Brenner, Hermann , Broeks, Annegien , Chanock, Stephen Jacob , Chenevix‐Trench, Georgia , Copson, Ellen , Couch, Fergus J, Cox, Angela , Cross, Simon S. , Devilee, Peter , Dunning, Alison M. , Easton, Douglas F. , Figueroa, Jonine D. , Glendon, Gord, González‐Neira, Anna , Hartikainen, Jaana M. , Hartman, Mikael , Heemskerk‐Gerritsen, Bernadette A. M. , Ho, Peh Joo , Hodge, James M. , Holleczek, Bernd , Hollestelle, Antoinette , Hooning, Maartje J. , Investigators, kConFab, Balleine, Rosemary L. , Bennett, Ian, Bogwitz, Michael R. , Bodek, Simon , Botes, Leon P., Buckley, Michael , Cohen, Paul A. , Crook, Ashley , Courtney, Eliza , Dawson, Sarah‐Jane , DeFazio, Anna , Delatycki, Martin B. , Duijf, Pascal H. G. , Fellows, Andrew, Fenton, Georgina L. , Flanagan, James M. , Forrest, Laura Elenor , Friedländer, Michael , Harraka, Philip A. , Kidd, Alexa, Kollias, James, Lakhani, Sunil R. , Lawrence, Mitchell, Lindeman, Geoffrey J. , Lippey, Jocelyn , Loi, Sherene , Reed, Amy E. McCart , Milne, Roger L , Gallego‐Ortega, David , Pathak, Gargi, Pearn, Amy , Robinson, Bridget A. , Skandarajah, Anita Rohini , Salisbury, Elizabeth, Saunders, Christobel , Saunus, Jodi M. , Savas, Peter Stephen , Sexton, Adrienne , Shelling, Andrew Neil , Simpson, Peter, Spurdle, Amanda B. , Visvader, Jane E. , Williams, Rachael, Tan, Bien‐Keem , Lim, Geok Hoon , Kaaks, Rudolf , Lawrence, Scott M. , Lissowska, Jolanta , Mannermaa, Arto , Manoochehri, Mehdi, Mesker, Wilma E. , Mulligan, Anna Marie , Obi, Nadia , Olson, Janet E. , Osório, Ana , Ottewell, Penelope Dawn , Patel, Alpa V , Pita, Guillermo , Rashid, Muhammad Usman , Ruddy, Kathryn J. , Schöttker, Ben , Seibold, Petra , Tapper, William , Teras, Lauren R , Timmermans, Mieke, Vachon, Celine M. , Wesseling, Jelle , Yadav, Siddhartha , Chang‐Claude, Jenny , Schmidt, Marjanka K. , Abubakar, Mustapha , García‐Closas, Montserrat

JNCI: Journal of the National Cancer Institute | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag244 | PMID 42498670 Get It

Abstract Background Breast cancer is etiologically heterogeneous, but which risk factors differ in their associations across tumor subtypes remains unclear. We conducted a large, pooled analysis to evaluate independent, dose-response associations between breast cancer risk factors and quantitative tumor features. Methods Analyses of 15,731 invasive breast cancers from 24 studies evaluated associations (p-trend) between reproductive and hormonal factors, body mass index (BMI), alcohol, smoking, and family history in relation to quantitative immunohistochemistry measures on tissue microarrays (ER, PR, HER2, KI67, TP53) and tumor grade. Analyses in a subset of 10 population-based studies estimated subtype-specific odds ratios (ORs) comparing cases to controls. A Bayesian False Discovery Probability (BFDP) &lt;0.2 was used to identify associations with strong statistical evidence. Results Nulliparity and later age at menopause were associated with higher ER-positivity (p-trend=0.021 and 0.001, respectively), with corresponding OR[ER+] (95% CI) = 1.49 (1.16-1.90) for nulliparous vs. parous and 1.07 (1.03-1.11) per 5 years. Current combined menopausal hormone therapy (MHT) use was associated with lower grade (p-trend&lt;0.001), with OR [grade1] = 3.37 (2.69-4.21) for current vs. never users. Higher BMI was associated with lower ER-positivity and higher grade in premenopausal women (p-trend&lt;0.001 and &lt;0.001), with OR[ER+] = 0.80 (0.74-0.87) and OR[grade1] = 0.75 (0.63-0.88) per 5 units, and with higher PR-positivity and higher grade in postmenopausal women (p-trend&lt;0.001 and &lt;0.001), with OR[PR+] = 1.08 (1.03-1.14) and OR[grade 3] = 1.10 (1.04-1.17) per 5 units. Conclusion This pooled analysis of 15,731 cases showed that nulliparity, age at menopause, MHT, and BMI have independent, dose-response associations with ER, PR, and grade, clarifying patterns of etiologic heterogeneity. Associations with HER2, KI67 and TP53, or other risk factors did not meet our threshold for strong evidence.
Acute Myeloid Leukemia Subtype‐Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy
Bolarinwa, Abiola , Al‐Kali, Aref , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Hefazi, Mehrdad , Matin, A, Elliott, Michelle A. , Litzow, Mark R. , Hogan, William J. , Patnaik, Mrinal M. , Pardanani, Animesh , Foran, James M. , Punwani, Nathan , Palmer, Jeanne , Sproat, Lisa Z., Reichard, Kaaren K., He, Rong , Viswanatha, David S., Zepeda‐Mendoza, Cinthya , Gangat, Naseema , Begna, Kebede H. , Tefferi, Ayalew , Saliba, Antoine N. , Alkhateeb, Hassan B , Mangaonkar, Abhishek A. , Saliba, Antoine N , Hefazi, Mehrdad , Elliott, Michelle , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Patnaik, Mrinal , Pardanani, Animesh , Foran, James M , Badar, Talha , Murthy, Hemant S , Chen, Dong , He, Rong , Zepeda-Mendoza, Cinthya J , Gangat, Naseema , Tefferi, Ayalew , Saliba, Antoine N , Bolarinwa, Abiola B , Alkhateeb, Hassan B. , Shah, Meera , Badar, Talha , Murthy, Hemant S. , Chen, Dong , Reichard, Kaaren K.

American Journal of Hematology | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70443 | PMID 42470254 Get It

ABSTRACT We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015–2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow‐up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core‐binding factor (CBF; N = 72; 13%), primary non‐CBF ( N = 403; 74%), post‐myelodysplastic syndromes (MDS) or post‐myelodysplastic/myeloproliferative neoplasms (post‐MDS‐MDS/MPN; N = 28; 5%), post‐MPN ( N = 15; 3%), and therapy‐related (t‐AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% ( p < 0.01) and 5‐year transplant‐censored survival rates 68%, 57%, 21%, 0%, and 55% ( p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non‐CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3 ‐ITD (OR 0.4; p < 0.01) or NPM1 MUT / FLT3 WT (OR 0.1; p < 0.01) superior CR/CRi while KRAS MUT (HR 8.8; p < 0.01), TP53 MUT (HR 5.4; p < 0.01), and TET2 MUT (HR 2.3; p = 0.01) predicted inferior and NPM1 MUT / FLT3 WT (HR 0.3; p = 0.01) superior survival. Prognostication in intensively‐treated AML should start with subtype specification and recognition of the limited value of NGS in non‐primary AML. Post‐MPN AML is particularly associated with dismal outcomes and should be prognostically distinguished from post‐MDS‐MDS/MPN AML. In primary non‐CBF AML, in addition to previously established risk factors, the favorable impact of FLT3 ‐ITD on achieving CR/CRi and the unfavorable impact of KRAS MUT and TET2 MUT on transplant‐censored survival were noted and require confirmation from additional studies.
Role of Communication Skills Training in Enhancing Medical Education and Care for Disorders of Gut‐Brain Interaction
Petrik, Megan , FOX, J, Singh, Manavjot , Mitsuhashi, Shuji , Wang, Xiao Jing , Fox, Jean, Simonetto, Douglas A , Wang, Xiao Jing , Simonetto, Douglas A.

Neurogastroenterology & Motility | July 18, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70400 | PMID 42470228 Get It

PathoBench: an open community-driven benchmark registry for pathogen bioinformatics tools
Dong, Yibo , Li, Na, Chiribau, Calin B., Mitchell, Molly, Liu, Xiaoming , Perkins, Andy

No container title available | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.16.739016 Get It

Abstract Summary The proliferation of pathogen bioinformatics pipelines has outpaced the community’s ability to compare them on common ground. Self-reported performance numbers, ad-hoc evaluation datasets, and inconsistent metrics make pipeline selection difficult for clinical and public-health researchers. We present PathoBench , an open web platform that addresses this gap through three coordinated mechanisms: (i) a curated registry of 26 standard benchmark datasets across 10 human pathogens, each with persistent identifiers and direct download links; (ii) pathogen-specific evaluation metrics that submissions must report, allowing direct head-to-head comparison only on the same dataset; and (iii) a credibility framework combining mandatory dataset attestation, ORCID-linked attribution, public peer comments, and administrator verification. As a case study, four published Mycobacterium tuberculosis drug-resistance pipelines were evaluated against the WHO TB mutation catalogue, demonstrating the framework’s discriminating power. PathoBench is open for community contributions across all ten supported pathogens. Availability and implementation PathoBench is freely available at https://pathobench.vercel.app . Source code is released under the MIT license at https://github.com/BPHL-Molecular/pathobench . The platform requires no installation for end users; programmatic access is available via a Supabase REST API. Contact yibo.dong@flhealth.gov Supplementary information Supplementary data are available at Bioinformatics online.